不同B细胞亚群在多发性硬化中的作用  

Role of different B cell subsets in multiple sclerosis

作　　者：孙美丽 李呼伦(指导)[1] SUN Meili;LI Hulun(Department of Neurobiology,Harbin Medical University,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学神经生物学教研室,哈尔滨150081

出　　处：《中国免疫学杂志》2022年第4期488-494,共7页Chinese Journal of Immunology

基　　金：国家自然科学基金重点项目(81430035);国家自然科学基金面上项目(81771305)资助。

摘　　要：多发性硬化(MS)是一种以中枢神经系统(CNS)脱髓鞘及持续的炎症反应为特征的神经自身免疫性疾病。长期以来MS被认为是由T细胞介导的疾病,然而,临床上MS抗CD20 B细胞耗竭治疗(BCDT)效果出人意料,凸显了B细胞在MS中的重要作用。但随着BCDT在MS中的应用,治疗后的副作用也显现出来。随着人们对B细胞知识的不断加深,了解不同B细胞亚群在疾病中的不同作用或许是找到解决临床副作用的关键。已知B细胞发育过程中不同B细胞亚群对MS的相对贡献目前还只是部分阐明。为此,本文主要从B细胞发育过程中不同B细胞亚群在MS中的相对贡献进行阐述,为深入探讨B细胞在MS发病机制和临床治疗策略中的作用提供科学思路。Multiple sclerosis(MS)is a neurological autoimmune disease characterized by central nervous system(CNS) demyelination and continuous inflammatory response. MS has long been regarded as a disease mediated by T cells. However,clinically,MS anti-CD20 B cell depletion therapy(BCDT)has unexpected results,highlighting the important role of B cells in MS. However,with the application of BCDT in MS,the side effects after treatment also appear. As people continue to deepen their knowledge of B cells,understanding the different roles of different B cell subsets in diseases may be the key to finding solutions to clinical side effects.It is known that the relative contribution of different B cell subsets to MS during the development of B cells is still only partially elucidated. For this reason,this article mainly discusses the relative contributions of different B cell subsets in MS during development of B cells,to provide scientific ideas for in-depth exploration of the role of B cells in the pathogenesis of MS and clinical treatment strategies.

关 键 词：B细胞亚群 多发性硬化 抗CD20 B细胞耗竭治疗(BCDT) 

分 类 号：R392[医药卫生—免疫学]